发明申请
WO2004076643A3 CIRCULATING TUMOR CELLS (CTC's): EARLY ASSESSMENT OF TIME TO PROGRESSION SURVIVAL AND RESPONSE TO THERAPY IN METASTATIC CANCER PATIENTS
审中-公开
基本信息:
- 专利标题： CIRCULATING TUMOR CELLS (CTC's): EARLY ASSESSMENT OF TIME TO PROGRESSION SURVIVAL AND RESPONSE TO THERAPY IN METASTATIC CANCER PATIENTS
- 专利标题（中）：循环肿瘤细胞（CTC）：早期评估进展生存时间和对分类癌症患者的治疗反应
- 申请号：PCT/US2004005848 申请日：2004-02-26
- 公开(公告)号：WO2004076643A3 公开(公告)日：2007-03-08
- 发明人： ALLARD JEFFREY W , CRISTOFANILLI MASSIMO , TERSTAPPEN LEON W M M
- 申请人： IMMUNIVEST CORP , ALLARD JEFFREY W , CRISTOFANILLI MASSIMO , TERSTAPPEN LEON W M M
- 专利权人： IMMUNIVEST CORP,ALLARD JEFFREY W,CRISTOFANILLI MASSIMO,TERSTAPPEN LEON W M M
- 当前专利权人： IMMUNIVEST CORP,ALLARD JEFFREY W,CRISTOFANILLI MASSIMO,TERSTAPPEN LEON W M M
- 优先权： US45051903 2003-02-27; US52475903 2003-11-25
- 主分类号： C12N1/00
- IPC分类号： C12N1/00 ; C12M1/34 ; C12N20060101 ; C12Q1/02 ; G01N33/48 ; G01N33/53 ; G01N33/543 ; G01N33/567 ; G01N33/574
摘要：
A cancer test having prognostic utility in predicting time to disease progression, overall survival, and response to therapy in patients with MBC based upon the presence and number of CTC's. The Cell Spotter® System is used to enumerate CTC's in blood. The system immunomagnetically concentrates epithelial cells, fluorescently labels the cells and identifies and quantifies CTC's. The absolute number of CTC's detected in the peripheral blood tumor load is, in part, a factor in prediction of survival, time to progression, and response to therapy. The mean time to survival of patients depended upon a threshold number of 5 CTC's per 7.5 ml of blood. Detection of CTC's in metastatic cancer represents a novel prognostic factor in patients with metastatic cancers, suggests a biological role for the presence of tumor cells in the blood, and indicates that the detection of CTC's could be considered an appropriate surrogate marker for prospective therapeutic clinical trials.
摘要（中）：
基于CTC的存在和数量，一种具有预测用于预测疾病进展时间，总体存活和对MBC患者的治疗反应的癌症测试。 CellSpotter®系统用于列举血液中的四氯化碳。 该系统免疫磁性浓缩上皮细胞，荧光标记细胞，识别和定量CTC。 在外周血肿瘤负荷中检测到的四氯化碳的绝对数量部分是预测生存期，进展时间和治疗反应的因素。 患者生存的平均时间取决于每7.5毫升血液的5个CTC的阈值数。 在转移性癌症中检测CTC代表转移癌患者的新型预后因素，表明血液中肿瘤细胞存在的生物学作用，并且表明CTC检测可被认为是前瞻性治疗性临床试验的适当替代标记 。